Physician profile
Xi Wang
NPI 1043797392
$982.04
in general payments reported to CMS, 2019-2025
24 companies · $185 in 2025
The $185 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $158 · 2023: $446 · 2024: $193 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $140.12 | 2022-2025 | Botox |
| Sk Life Science, INC. | $123.77 | 2022-2024 | Xcopri |
| Livanova USA, INC. | $103.21 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $51.73 | 2022-2023 | |
| Neuropace, INC. | $50.70 | 2022 | |
| Pfizer INC. | $46.51 | 2024-2025 | |
| Neurelis, INC. | $39.41 | 2022-2023 | Valtoco |
| Neurocrine Biosciences, INC. | $37.34 | 2023 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $36.37 | 2023-2024 | Gocovri, Gocovri |
| Axsome Therapeutics, INC. | $35.98 | 2025 | Symbravo |
| Csl Behring | $35.54 | 2023 | Hizentra |
| Tg Therapeutics, INC. | $34.14 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $31.31 | 2023 | Rexulti |
| Harmony Biosciences LLC | $30.60 | 2023-2024 | Wakix |
| Jazz Pharmaceuticals INC. | $28.16 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $21.01 | 2024 | Hyqvia |
| Argenx US, INC. | $19.31 | 2024 | |
| Emd Serono, INC. | $19.08 | 2023 | Mavenclad |
| Impel Pharmaceuticals INC. | $18.38 | 2023 | Trudhesa |
| Alexion Pharmaceuticals, INC. | $17.23 | 2023 | Ultomiris |
| Amylyx Pharmaceuticals, INC. | $17.12 | 2023 | Relyvrio |
| Celgene Corporation | $17.06 | 2023 | Zeposia |
| Biogen, INC. | $15.07 | 2023 | Vumerity |
| Bio Products Laboratory USA, INC. | $12.89 | 2023 | Coagadex, Gammaplex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xi Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.